
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences Inc. shows a positive outlook driven by encouraging initial results from its SENTI-202 therapy, which outperformed current therapies with <33% complete response rates, indicating strong potential for future clinical success. The company is also focusing on enhancing its operational efficiency by investing in in-house GMP manufacturing capabilities, which could reduce costs and improve production timelines for its innovative therapies. The anticipated results from ongoing clinical trials, particularly those expected in 4Q25, suggest the possibility of significant upside potential if patient outcomes continue to surpass benchmarks while maintaining durable responses.
Bears say
The analysis highlights a potential negative outlook for Senti Biosciences Inc., primarily due to the risk-adjusted projections and price targets that may face downward revisions. The recurring emphasis on the possibility of adjustments indicates concerns regarding the stability and performance of the company’s financial metrics. Consequently, the likelihood of adverse modifications to financial forecasts further underlines the inherent financial risks associated with Senti Biosciences's current and future operations in the highly competitive biotechnology sector.
This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares